Success Stories: NIW Petition Approved for a Principal Scientist from Canada in the Field of Oncology with the Help of Our Legal Team’s Diligence
Client’s Testimonial:
“It has been a pleasure working with you to date. I appreciate the responsiveness and your care in preparing high-quality and consistent documents. I look forward to receiving your guidance in the next steps of my application!”
On March 16th, 2021, we received another EB-2 NIW (National Interest Waiver) approval for a Principal Scientist in the Field of Oncology (Approval Notice).
General Field: Oncology
Position at the Time of Case Filing: Principal Scientist
Country of Origin: Canada
State of Residence at the Time of Filing: California
Approval Notice Date: March 16th, 2021
Processing Time: 7 months, 15 days
Case Summary:
A principal scientist from Canada appointed the expert services of North America Immigration Law Group (NAILG) to help her in preparing an EB-2 NIW (National Interest Waiver) petition. After a diligent evaluation of our client’s credentials, we asserted that she was a well-qualified resource to the United States and must acquire the national interest waiver. When our client signed the contract with us, we started preparing a strong case on her behalf.
Described our client’s research briefly:
We explored that she held a Ph.D. in cellular and molecular medicine, intending her research on the mechanisms of cancer initiation and progression to identify and characterize cancer-causing molecules in specific genetic contexts and cancer types, the mechanism of action of oncology drugs, and biomarkers that predict patient response or resistance to therapeutic agents. Consequently, her research in this area is of great importance because the information obtained through her work leads to a deeper understanding of how specific oncology drugs work based on one’s genetic, molecular, and cellular profiles, allowing for the accurate prediction of which patient populations benefit most from the drugs, as well as novel strategies to improve patient clinical response and overcome drug resistance.
Elaborated on her Publications, Citation Count & Funds Grant:
We determined that our client not only completed her research in this field but also had an advantageous impact on her peers. Her 20 peer-reviewed journal articles (6 of them first-authored) and 1 book chapter accumulated 1,751 citations. Since citations in the scientific literature indicate the use of a researcher’s work in pursuance of other studies, it follows that a higher rate of citation shows a researcher’s greater impact in their field. Therefore, this outstanding record at which her papers have been cited indicates that others in her discipline have relied on her results extraordinarily. Moving ahead, we also noted that in recognition of the value and importance of our client’s work, it has been granted funding by the Canadian Institutes of Health Research (CIHR). This institution is dedicated to supporting discoveries and innovations that improve health and strengthen the healthcare system, and funding is incredibly competitive, demonstrating the significance of her research and success in the field.
Gathered more evidence:
To verify the provided testimonies, we suggested if she could manage a few letters of recommendation from peers to attach in her petition packet, and she successfully obtained two recommendation letters from fellow specialists in the same field supporting her research holding substantial merit and national importance.
Successfully received the Approval:
We victoriously convinced the USCIS that our client’s work offers effective benefits to the biopharmaceutical industry as it is a significant contributor to the national economy in the United States. The NAILG team congratulates her for obtaining NIW approval. Also, we thank our client for choosing us to represent her case.